Biotech’s biggest investor is prepping a whopping $4.75B wager on the future of the industry
Don’t expect a little thing like a market meltdown in the biotech sector to slow the OrbiMed Advisors juggernaut in 2022.
The sector’s largest single investor just signaled Wall Street that it plans to raise $1.9 billion for its next flagship fund, a year after its last go-round with $1.5 billion — which itself set a record during the big biopharma pandemic boom. And that’s not all. OrbiMed Asia’s group posted a Form D on a $1.1 billion raise for its efforts. Its royalty and patent arm, meanwhile, is out beating the bushes for $1.75 billion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.